Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Treatment Administration
| Pyrotinib Treatment | Total (N=171) |
|---|---|
| Lines of pyrotinib-based therapy | |
| 1 | 46 (26.9%) |
| ≥2 | 125 (73.1%) |
| Starting dose of pyrotinib (mg/day) | |
| 400 | 100 (58.5%) |
| 320 | 66 (38.6%) |
| 240 | 4 (2.3%) |
| 160 | 1 (0.6%) |
| Treatment regimens | |
| Pyrotinib + chemotherapy | 150 (87.7%) |
| Pyrotinib + capecitabine | 111 (64.9%) |
| Pyrotinib + others | 39 (22.8%) |
| Pyrotinib + endocrine therapy | 10 (5.8%) |
| Pyrotinib + trastuzumab | 1 (0.6%) |
| Pyrotinib + trastuzumab + chemotherapy | 1 (0.6%) |
| Pyrotinib monotherapy | 9 (5.3%) |
